{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Buhrow SA"],"funding":["CCR NIH HHS","National Cancer Institute","Mayo Clinic","NCI NIH HHS","National Institutes of Health"],"pagination":["123654"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10249430"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["1221"],"pubmed_abstract":["The selective estrogen receptor modifier tamoxifen (TAM) is widely used for the treatment of women with estrogen receptor positive (ER+ ) breast cancer. Endoxifen (ENDX) is a potent, active metabolite of TAM and is important for TAM's clinical activity. While multiple papers have been published regarding TAM metabolism, few studies have examined or quantified the metabolism of ENDX. To quantify ENDX and its metabolites in patient plasma samples, we have developed and validated a rapid, sensitive, and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of the E- and Z-isomers of ENDX (0.5-500 ng/ml) and the ENDX metabolites norendoxifen (1-500 and 0.5-500 ng/ml E and Z, respectfully), ENDX catechol (3.075-307.5 and 1.92-192 ng/ml E an"],"journal":["Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"],"pubmed_title":["Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer."],"pmcid":["PMC10249430"],"funding_grant_id":["N01 CM052206","HHSN261200800001E","HHSN261200800001C","U01 CA069912","HHSN261201100014C","P30 CA015083","UO1 CA69912","N01-CM52206","P50CA 116201","P50 CA116201","P30 CA15083"],"pubmed_authors":["Buhrow SA","Goetz MP","Reid JM","Koubek EJ","Ames MM"],"additional_accession":[]},"is_claimable":false,"name":"Development and validation of a liquid chromatography-mass spectrometry assay for quantification of Z- and E- isomers of endoxifen and its metabolites in plasma from women with estrogen receptor positive breast cancer.","description":"The selective estrogen receptor modifier tamoxifen (TAM) is widely used for the treatment of women with estrogen receptor positive (ER+ ) breast cancer. Endoxifen (ENDX) is a potent, active metabolite of TAM and is important for TAM's clinical activity. While multiple papers have been published regarding TAM metabolism, few studies have examined or quantified the metabolism of ENDX. To quantify ENDX and its metabolites in patient plasma samples, we have developed and validated a rapid, sensitive, and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of the E- and Z-isomers of ENDX (0.5-500 ng/ml) and the ENDX metabolites norendoxifen (1-500 and 0.5-500 ng/ml E and Z, respectfully), ENDX catechol (3.075-307.5 and 1.92-192 ng/ml E an","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-05-28T21:58:15.708Z","creation":"2024-12-03T15:23:56.688Z"},"accession":"S-EPMC10249430","cross_references":{"pubmed":["37004493"],"doi":["10.1016/j.jchromb.2023.123654"]}}